Phylogenetic group/subgroup distribution of the 146 mcr-negative colistin-resistant E. coli with their resistance and virulence characteristics
| Phylogenetic group/subgroup . | Strains, n (%) . | PmrA/PmrB mutationa, n (%) . | ESBL, n (%) . | Ampicillin resistance, n (%) . | Tetracycline resistance, n (%) . | Sulphonamide and/or trimethoprim resistance, n (%) . | Phenicol resistance, n (%) . | Intestinal pathogenic E. coli virulence gene score, M (min–max) . | Extra-intestinal E. coli virulence gene score, M (min–max) . |
|---|---|---|---|---|---|---|---|---|---|
| A | 17 (11.6) | 10 (58.8) | 2 (11.8) | 9 (52.9) | 5 (29.4) | 5 (29.4) | 2 (11.8) | 0.1 (0–1) | 2.8 (0–6) |
| B1 | 12 (8.2) | 10 (83.3) | 1 (8.3) | 6 (50.0) | 4 (33.3) | 6 (50.0) | 1 (8.3) | 0.3 (0–2) | 2.6 (0–9) |
| CC87 | 3 (25.0) | 3 (100.0) | 0 | 3 (100.0) | 3 (100.0) | 3 (100.0) | 1 (33.3) | 0.3 (0–1) | 7.3 (6–9) |
| B2 | 68 (46.6) | 48 (70.6) | 11 (16.2) | 36 (52.9) | 20 (29.4) | 26 (38.2) | 4 (5.9) | 0.0 (0–1) | 10.4 (3–17) |
| I ST131 | 14 (20.6) | 12 (85.7) | 9 (64.3) | 14 (100.0) | 9 (64.3) | 8 (57.1) | 2 (14.3) | 0.1 (0–1) | 8.8 (5–12) |
| I non-ST131 | 3 (4.4) | 3 (100.0) | 0 | 2 (66.7) | 2 (66.7) | 1 (33.3) | 0 | 0.0 (0–0) | 7.3 (6–9) |
| II | 17 (25) | 9 (52.9) | 0 | 8 (47.1) | 2 (11.8) | 7 (41.2) | 1 (5.9) | 0.0 (0–0) | 13.2 (7–17) |
| III | 1 (1.5) | 1 (100.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 12.0 (12–12) |
| IV | 2 (2.9) | 2 (100.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 9.0 (6–12) |
| V | 1 (1.5) | 1 (100.0) | 0 | 1 (100.0) | 0 | 1 (100.0) | 0 | 0.0 (0–0) | 12 (12–12) |
| VI | 4 (5.9) | 3 (75.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 11.8 (11–12) |
| VII | 11 (16.2) | 4 (36.4) | 0 | 9 (81.8) | 4 (36.4) | 5 (45.5) | 0 | 0.1 (0–1) | 9.1 (6–13) |
| IX | 7 (10.3) | 6 (85.7) | 1 (14.3) | 1 (14.3) | 1 (14.3) | 2 (28.6) | 1 (14.3) | 0.0 (0–0) | 11.9 (10–14) |
| UA | 8 (11.8) | 7 (87.5) | 1 (12.5) | 1 (12.5) | 2 (25.0) | 2 (25.0) | 0 | 0.0 (0–0) | 8.6 (3–13) |
| C | 4 (2.7) | 4 (100.0) | 0 | 3 (75.0) | 4 (100.0) | 3 (75.0) | 3 (75.0) | 0.3 (0–1) | 8.3 (7–10) |
| D | 29 (19.9) | 24 (82.8) | 4 (13.8) | 23 (79.3) | 12 (41.4) | 18 (62.1) | 4 (13.8) | 0.2 (0–2) | 5.9 (0–11) |
| CGA | 20 (69.0) | 16 (80.0) | 2 (10.0) | 17 (85.0) | 11 (55.0) | 13 (65.0) | 2 (10.0) | 0.0 (0–0) | 7.2 (1–11) |
| non-CGA | 9 (31.0) | 8 (88.9) | 2 (22.2) | 6 (66.7) | 1 (11.1) | 5 (55.6) | 2 (22.2) | 0.6 (0–2) | 3.1 (0–6) |
| E | 3 (2.1) | 3 (100.0) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 1 (33.3) | 0 | 0.0 (0–0) | 3.3 (1–5) |
| F | 12 (8.2) | 7 (58.3) | 1 (8.3) | 5 (41.7) | 2 (16.7) | 6 (50.0) | 1 (8.3) | 0.1 (0–1) | 7.3 (4–12) |
| Clade V | 1 (0.7) | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 0.0 (0–0) |
| Total | 146 (100.0) | 106 (72.6) | 20 (13.7) | 83 (56.8) | 47 (32.2) | 65 (44.5) | 15 (10.3) | 0.1 (0–2) | 7.5 (0–17) |
| Phylogenetic group/subgroup . | Strains, n (%) . | PmrA/PmrB mutationa, n (%) . | ESBL, n (%) . | Ampicillin resistance, n (%) . | Tetracycline resistance, n (%) . | Sulphonamide and/or trimethoprim resistance, n (%) . | Phenicol resistance, n (%) . | Intestinal pathogenic E. coli virulence gene score, M (min–max) . | Extra-intestinal E. coli virulence gene score, M (min–max) . |
|---|---|---|---|---|---|---|---|---|---|
| A | 17 (11.6) | 10 (58.8) | 2 (11.8) | 9 (52.9) | 5 (29.4) | 5 (29.4) | 2 (11.8) | 0.1 (0–1) | 2.8 (0–6) |
| B1 | 12 (8.2) | 10 (83.3) | 1 (8.3) | 6 (50.0) | 4 (33.3) | 6 (50.0) | 1 (8.3) | 0.3 (0–2) | 2.6 (0–9) |
| CC87 | 3 (25.0) | 3 (100.0) | 0 | 3 (100.0) | 3 (100.0) | 3 (100.0) | 1 (33.3) | 0.3 (0–1) | 7.3 (6–9) |
| B2 | 68 (46.6) | 48 (70.6) | 11 (16.2) | 36 (52.9) | 20 (29.4) | 26 (38.2) | 4 (5.9) | 0.0 (0–1) | 10.4 (3–17) |
| I ST131 | 14 (20.6) | 12 (85.7) | 9 (64.3) | 14 (100.0) | 9 (64.3) | 8 (57.1) | 2 (14.3) | 0.1 (0–1) | 8.8 (5–12) |
| I non-ST131 | 3 (4.4) | 3 (100.0) | 0 | 2 (66.7) | 2 (66.7) | 1 (33.3) | 0 | 0.0 (0–0) | 7.3 (6–9) |
| II | 17 (25) | 9 (52.9) | 0 | 8 (47.1) | 2 (11.8) | 7 (41.2) | 1 (5.9) | 0.0 (0–0) | 13.2 (7–17) |
| III | 1 (1.5) | 1 (100.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 12.0 (12–12) |
| IV | 2 (2.9) | 2 (100.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 9.0 (6–12) |
| V | 1 (1.5) | 1 (100.0) | 0 | 1 (100.0) | 0 | 1 (100.0) | 0 | 0.0 (0–0) | 12 (12–12) |
| VI | 4 (5.9) | 3 (75.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 11.8 (11–12) |
| VII | 11 (16.2) | 4 (36.4) | 0 | 9 (81.8) | 4 (36.4) | 5 (45.5) | 0 | 0.1 (0–1) | 9.1 (6–13) |
| IX | 7 (10.3) | 6 (85.7) | 1 (14.3) | 1 (14.3) | 1 (14.3) | 2 (28.6) | 1 (14.3) | 0.0 (0–0) | 11.9 (10–14) |
| UA | 8 (11.8) | 7 (87.5) | 1 (12.5) | 1 (12.5) | 2 (25.0) | 2 (25.0) | 0 | 0.0 (0–0) | 8.6 (3–13) |
| C | 4 (2.7) | 4 (100.0) | 0 | 3 (75.0) | 4 (100.0) | 3 (75.0) | 3 (75.0) | 0.3 (0–1) | 8.3 (7–10) |
| D | 29 (19.9) | 24 (82.8) | 4 (13.8) | 23 (79.3) | 12 (41.4) | 18 (62.1) | 4 (13.8) | 0.2 (0–2) | 5.9 (0–11) |
| CGA | 20 (69.0) | 16 (80.0) | 2 (10.0) | 17 (85.0) | 11 (55.0) | 13 (65.0) | 2 (10.0) | 0.0 (0–0) | 7.2 (1–11) |
| non-CGA | 9 (31.0) | 8 (88.9) | 2 (22.2) | 6 (66.7) | 1 (11.1) | 5 (55.6) | 2 (22.2) | 0.6 (0–2) | 3.1 (0–6) |
| E | 3 (2.1) | 3 (100.0) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 1 (33.3) | 0 | 0.0 (0–0) | 3.3 (1–5) |
| F | 12 (8.2) | 7 (58.3) | 1 (8.3) | 5 (41.7) | 2 (16.7) | 6 (50.0) | 1 (8.3) | 0.1 (0–1) | 7.3 (4–12) |
| Clade V | 1 (0.7) | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 0.0 (0–0) |
| Total | 146 (100.0) | 106 (72.6) | 20 (13.7) | 83 (56.8) | 47 (32.2) | 65 (44.5) | 15 (10.3) | 0.1 (0–2) | 7.5 (0–17) |
Missense mutations previously reported to be associated with colistin resistance as well as mutations modifying the length of the protein were considered. For the sake of clarity, strain 130A belonging to ST131 and exhibiting two mutations (one in PmrA and one in PmrB) was scored with a unique mutation.
Phylogenetic group/subgroup distribution of the 146 mcr-negative colistin-resistant E. coli with their resistance and virulence characteristics
| Phylogenetic group/subgroup . | Strains, n (%) . | PmrA/PmrB mutationa, n (%) . | ESBL, n (%) . | Ampicillin resistance, n (%) . | Tetracycline resistance, n (%) . | Sulphonamide and/or trimethoprim resistance, n (%) . | Phenicol resistance, n (%) . | Intestinal pathogenic E. coli virulence gene score, M (min–max) . | Extra-intestinal E. coli virulence gene score, M (min–max) . |
|---|---|---|---|---|---|---|---|---|---|
| A | 17 (11.6) | 10 (58.8) | 2 (11.8) | 9 (52.9) | 5 (29.4) | 5 (29.4) | 2 (11.8) | 0.1 (0–1) | 2.8 (0–6) |
| B1 | 12 (8.2) | 10 (83.3) | 1 (8.3) | 6 (50.0) | 4 (33.3) | 6 (50.0) | 1 (8.3) | 0.3 (0–2) | 2.6 (0–9) |
| CC87 | 3 (25.0) | 3 (100.0) | 0 | 3 (100.0) | 3 (100.0) | 3 (100.0) | 1 (33.3) | 0.3 (0–1) | 7.3 (6–9) |
| B2 | 68 (46.6) | 48 (70.6) | 11 (16.2) | 36 (52.9) | 20 (29.4) | 26 (38.2) | 4 (5.9) | 0.0 (0–1) | 10.4 (3–17) |
| I ST131 | 14 (20.6) | 12 (85.7) | 9 (64.3) | 14 (100.0) | 9 (64.3) | 8 (57.1) | 2 (14.3) | 0.1 (0–1) | 8.8 (5–12) |
| I non-ST131 | 3 (4.4) | 3 (100.0) | 0 | 2 (66.7) | 2 (66.7) | 1 (33.3) | 0 | 0.0 (0–0) | 7.3 (6–9) |
| II | 17 (25) | 9 (52.9) | 0 | 8 (47.1) | 2 (11.8) | 7 (41.2) | 1 (5.9) | 0.0 (0–0) | 13.2 (7–17) |
| III | 1 (1.5) | 1 (100.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 12.0 (12–12) |
| IV | 2 (2.9) | 2 (100.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 9.0 (6–12) |
| V | 1 (1.5) | 1 (100.0) | 0 | 1 (100.0) | 0 | 1 (100.0) | 0 | 0.0 (0–0) | 12 (12–12) |
| VI | 4 (5.9) | 3 (75.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 11.8 (11–12) |
| VII | 11 (16.2) | 4 (36.4) | 0 | 9 (81.8) | 4 (36.4) | 5 (45.5) | 0 | 0.1 (0–1) | 9.1 (6–13) |
| IX | 7 (10.3) | 6 (85.7) | 1 (14.3) | 1 (14.3) | 1 (14.3) | 2 (28.6) | 1 (14.3) | 0.0 (0–0) | 11.9 (10–14) |
| UA | 8 (11.8) | 7 (87.5) | 1 (12.5) | 1 (12.5) | 2 (25.0) | 2 (25.0) | 0 | 0.0 (0–0) | 8.6 (3–13) |
| C | 4 (2.7) | 4 (100.0) | 0 | 3 (75.0) | 4 (100.0) | 3 (75.0) | 3 (75.0) | 0.3 (0–1) | 8.3 (7–10) |
| D | 29 (19.9) | 24 (82.8) | 4 (13.8) | 23 (79.3) | 12 (41.4) | 18 (62.1) | 4 (13.8) | 0.2 (0–2) | 5.9 (0–11) |
| CGA | 20 (69.0) | 16 (80.0) | 2 (10.0) | 17 (85.0) | 11 (55.0) | 13 (65.0) | 2 (10.0) | 0.0 (0–0) | 7.2 (1–11) |
| non-CGA | 9 (31.0) | 8 (88.9) | 2 (22.2) | 6 (66.7) | 1 (11.1) | 5 (55.6) | 2 (22.2) | 0.6 (0–2) | 3.1 (0–6) |
| E | 3 (2.1) | 3 (100.0) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 1 (33.3) | 0 | 0.0 (0–0) | 3.3 (1–5) |
| F | 12 (8.2) | 7 (58.3) | 1 (8.3) | 5 (41.7) | 2 (16.7) | 6 (50.0) | 1 (8.3) | 0.1 (0–1) | 7.3 (4–12) |
| Clade V | 1 (0.7) | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 0.0 (0–0) |
| Total | 146 (100.0) | 106 (72.6) | 20 (13.7) | 83 (56.8) | 47 (32.2) | 65 (44.5) | 15 (10.3) | 0.1 (0–2) | 7.5 (0–17) |
| Phylogenetic group/subgroup . | Strains, n (%) . | PmrA/PmrB mutationa, n (%) . | ESBL, n (%) . | Ampicillin resistance, n (%) . | Tetracycline resistance, n (%) . | Sulphonamide and/or trimethoprim resistance, n (%) . | Phenicol resistance, n (%) . | Intestinal pathogenic E. coli virulence gene score, M (min–max) . | Extra-intestinal E. coli virulence gene score, M (min–max) . |
|---|---|---|---|---|---|---|---|---|---|
| A | 17 (11.6) | 10 (58.8) | 2 (11.8) | 9 (52.9) | 5 (29.4) | 5 (29.4) | 2 (11.8) | 0.1 (0–1) | 2.8 (0–6) |
| B1 | 12 (8.2) | 10 (83.3) | 1 (8.3) | 6 (50.0) | 4 (33.3) | 6 (50.0) | 1 (8.3) | 0.3 (0–2) | 2.6 (0–9) |
| CC87 | 3 (25.0) | 3 (100.0) | 0 | 3 (100.0) | 3 (100.0) | 3 (100.0) | 1 (33.3) | 0.3 (0–1) | 7.3 (6–9) |
| B2 | 68 (46.6) | 48 (70.6) | 11 (16.2) | 36 (52.9) | 20 (29.4) | 26 (38.2) | 4 (5.9) | 0.0 (0–1) | 10.4 (3–17) |
| I ST131 | 14 (20.6) | 12 (85.7) | 9 (64.3) | 14 (100.0) | 9 (64.3) | 8 (57.1) | 2 (14.3) | 0.1 (0–1) | 8.8 (5–12) |
| I non-ST131 | 3 (4.4) | 3 (100.0) | 0 | 2 (66.7) | 2 (66.7) | 1 (33.3) | 0 | 0.0 (0–0) | 7.3 (6–9) |
| II | 17 (25) | 9 (52.9) | 0 | 8 (47.1) | 2 (11.8) | 7 (41.2) | 1 (5.9) | 0.0 (0–0) | 13.2 (7–17) |
| III | 1 (1.5) | 1 (100.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 12.0 (12–12) |
| IV | 2 (2.9) | 2 (100.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 9.0 (6–12) |
| V | 1 (1.5) | 1 (100.0) | 0 | 1 (100.0) | 0 | 1 (100.0) | 0 | 0.0 (0–0) | 12 (12–12) |
| VI | 4 (5.9) | 3 (75.0) | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 11.8 (11–12) |
| VII | 11 (16.2) | 4 (36.4) | 0 | 9 (81.8) | 4 (36.4) | 5 (45.5) | 0 | 0.1 (0–1) | 9.1 (6–13) |
| IX | 7 (10.3) | 6 (85.7) | 1 (14.3) | 1 (14.3) | 1 (14.3) | 2 (28.6) | 1 (14.3) | 0.0 (0–0) | 11.9 (10–14) |
| UA | 8 (11.8) | 7 (87.5) | 1 (12.5) | 1 (12.5) | 2 (25.0) | 2 (25.0) | 0 | 0.0 (0–0) | 8.6 (3–13) |
| C | 4 (2.7) | 4 (100.0) | 0 | 3 (75.0) | 4 (100.0) | 3 (75.0) | 3 (75.0) | 0.3 (0–1) | 8.3 (7–10) |
| D | 29 (19.9) | 24 (82.8) | 4 (13.8) | 23 (79.3) | 12 (41.4) | 18 (62.1) | 4 (13.8) | 0.2 (0–2) | 5.9 (0–11) |
| CGA | 20 (69.0) | 16 (80.0) | 2 (10.0) | 17 (85.0) | 11 (55.0) | 13 (65.0) | 2 (10.0) | 0.0 (0–0) | 7.2 (1–11) |
| non-CGA | 9 (31.0) | 8 (88.9) | 2 (22.2) | 6 (66.7) | 1 (11.1) | 5 (55.6) | 2 (22.2) | 0.6 (0–2) | 3.1 (0–6) |
| E | 3 (2.1) | 3 (100.0) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 1 (33.3) | 0 | 0.0 (0–0) | 3.3 (1–5) |
| F | 12 (8.2) | 7 (58.3) | 1 (8.3) | 5 (41.7) | 2 (16.7) | 6 (50.0) | 1 (8.3) | 0.1 (0–1) | 7.3 (4–12) |
| Clade V | 1 (0.7) | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 (0–0) | 0.0 (0–0) |
| Total | 146 (100.0) | 106 (72.6) | 20 (13.7) | 83 (56.8) | 47 (32.2) | 65 (44.5) | 15 (10.3) | 0.1 (0–2) | 7.5 (0–17) |
Missense mutations previously reported to be associated with colistin resistance as well as mutations modifying the length of the protein were considered. For the sake of clarity, strain 130A belonging to ST131 and exhibiting two mutations (one in PmrA and one in PmrB) was scored with a unique mutation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
